Bradner, Gray explore targeted degradation-based model systems

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray published a paper in Nature Chemical Biology demonstrating a generalizable target-specific protein degradation system that can be used to create

Read the full 294 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE